Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the fourth quarter and year ended December 31, 2015.
Healthcare analysts weighed in on development-stage company Celldex Therapeutics, Inc. (NASDAQ:CLDX) and biopharmaceutical firm Mast Therapeutics (NYSEMKT:MSTX).
Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented mature survival data from the Company’s randomized, double-blind Phase 2 study of RINTEGA® (rindopepimut) in patients with EGFRvIII-positive, …
Analysts are weighing in on the development-stage company Celldex Therapeutics, Inc. (NASDAQ:CLDX) and pharmaceutical company Lexicon Pharmaceuticals, Inc.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented new preclinical data on varlilumab, a fully human monoclonal agonist antibody that binds and activates CD27, a critical co-stimulatory …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the third quarter ended September 30, 2015.
Cowen analyst Boris Peaker was out pounding the table on Celldex Therapeutics, Inc. (NASDAQ:CLDX) Tuesday, reiterating an Outperform rating and price target of $28, which …
Recently, various executives have taken part in insider buying activity for the stocks of Cytori Therapeutics Inc (NASDAQ:CYTX), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Nuance Communications Inc.
Recently, various executives have taken part in insider trading activity for the stocks of Skyworks Solutions Inc (NASDAQ:SWKS), Palo Alto Networks Inc (NYSE:PANW), Celldex Therapeutics, …
In a research report released yesterday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), and reduced …
